OMGA
Omega Therapeutics, Inc.
Set alert
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.166
- Prev close
- 0.1426
- Mkt cap
- 44.90M
- Vol
- 4.28M
- Avg vol
- 315.41K
- EPS
- -1.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1426
- High
- 0.166
- Forward P/E
- -0.89
- Beta
- 1.84
- Short ratio
- 16.34
- Inst. own
- 90.43%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 1.00
- 200-d avg
- 1.82
- 1y target
- 9.50
Key statistics
- Market cap
- 44.90M
- Enterprise value
- 126.79M
- Trailing P/E
- 0.00
- Forward P/E
- -0.89
- PEG ratio
- 0.00
- Price / sales
- 7.11
- Price / book
- 0.77
- EPS (TTM)
- -1.32
- Beta
- 1.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 6.31M
- Revenue growth
- 181.20%
- Free cash flow
- -41.81M
- Total cash
- 45.85M
- Total debt
- 126.95M
- Return on equity
- -129.15%
- Shares outstanding
- 55.37M
- Short % of float
- 33.20%
- 50-day average
- 1.00
- 200-day average
- 1.82
Analyst view
Consensus: none
- Target (low)
- 4.00
- Target (mean)
- 9.50
- Target (high)
- 12.00
- Strong buy2
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.26333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.29 | -0.30 | -0.01 | -3.45% |
| Aug 6, 2024 | Jun 1, 2024 | -0.36 | — | — | — |
| Aug 6, 2024 | Jun 1, 2024 | -0.36 | -0.30 | +0.06 | +16.67% |
| May 6, 2024 | Mar 1, 2024 | -0.38 | — | — | — |
| May 6, 2024 | Mar 1, 2024 | -0.38 | -0.36 | +0.02 | +5.26% |
| Mar 28, 2024 | Dec 1, 2023 | -0.46 | -0.37 | +0.09 | +19.57% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Piper Sandler | main | Overweight | Overweight |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 7, 2024 | Wedbush | reit | Outperform | Outperform |
| Aug 7, 2024 | Chardan Capital | main | Buy | Buy |
| Jun 18, 2024 | Raymond James | init | — | Outperform |
| May 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Omega Therapeutics, Inc.
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- omegatherapeutics.com
News
- Omega Pacific Commences Drill Program at Williams Property
- Omega Pacific Williams Property Exploration Program Update
- Omega Pacific Outlines 2026 Exploration Program at the Williams Property
- Omega Pacific Closes First Tranche of Non-Brokered Private Placement
- Omega Pacific Clarifies Size of Previously Announced Private Placement
- Omega Pacific Announces Non-Brokered Private Placement
- Omega Pacific Acquires 100% of Williams Property
- Omega Pacific Closes Non-Brokered Private Placement
- Omega Pacific Closes First Tranche of Offering
- Omega Pacific Announces Private Placement
Your note
Sign in to keep a note on OMGA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FLAGSHIP PIONEERING, INC. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 26, 2023 | 0 |
| YOUNG RICHARD A | Director | Sale | Jun 1, 2023 | 739,118 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Flagship Pioneering Inc. | 52.79% | 29,225,579 | 23.70M | Sep 29, 2024 |
| FMR, LLC | 10.95% | 6,062,104 | 4.92M | Sep 29, 2024 |
| Harbourvest Partners, LLC | 6.34% | 3,512,110 | 2.85M | Sep 29, 2024 |
| State Of Wisconsin Investment Board | 3.35% | 1,857,265 | 1.51M | Sep 29, 2024 |
| Siren, L.L.C. | 2.39% | 1,323,530 | 1.07M | Sep 29, 2024 |
| Vanguard Group Inc | 2.01% | 1,114,731 | 904.05K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 3.63% | 2,012,406 | 1.63M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.41% | 779,100 | 631.85K | Sep 29, 2024 |
| Fidelity Growth Company K6 Fund | 1.36% | 752,855 | 610.57K | Oct 30, 2024 |
| Fidelity Series Growth Company Fund | 0.79% | 434,979 | 352.77K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.56% | 309,866 | 251.30K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.22% | 123,532 | 100.18K | Oct 30, 2024 |